Dezocine

CHEMBL1685 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

245.4 g/mol

LogP

3.7

Phase

4

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

Molekularmasse

245,3600 g/mol

LogP

3,70

TPSA

46,30 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pain Management

Wirkmechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N

InChI

InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1

Molecular Formula

C16H23NO

HBD / HBA

2 / 2

Rotierbare Bindungen

0

Schwere Atome

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dezocine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1685. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Dezocine auf PillFYI

Struktur

Schnelldaten

Formel: C16H23NO

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.